Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …

Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …

Importance Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …

It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …

Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …

Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …